



PERSONAL INFORMATION

Name
Address
Telephone
Fax
E-mail

Monica Fortini
VIA DELLE VIGNE, 7- 44121, FERRARA (ITALY)
+39 348 3579559

ufficio-lh@unife.it / monica.fortini@ospfe.it
PEC: monica.fortini@biologo.onb.it

Nationality

Italian

Date of birth

08/09/1959

WORK EXPERIENCE

- Dates (from – to)
- Name and address of employer
- Type of business or sector

- Occupation or position held
- Main activities and responsibilities

15 March 2012 – 31 May 2014

Consorzio Ferrara Ricerche – University of Ferrara - Via Savonarola, 9 – 44121 Ferrara (Italy)

Unit of *Thalassaemia&Haemoglobinopathies (DHTE)*– Department of Growth and Development-Azienda Ospedaliero-Universitaria S.Anna, Cona-Ferrara (Italy)

Clinical Research Coordinator, Clinical data manager

Clinical Research Coordinator and Clinical Laboratory Management in accordance with study protocol requirements and in compliance with ICH – GCP guidelines. Clinical research protocols:

1. 2012-101 (EudraCT 2012-000955-15, *Deferasirox associated with antiviral therapy*, Novartis);
2. CICAL670E20011, *Deferasirox treatment of iron overload in patient with non-transfusion-dependent beta-thalassaemia intermedia* (Novartis)
3. CICAL670F2201 (EudraCT 2013-004167-32, Novartis) *A randomized, open-label, multicenter, two arm, phase II study to investigate the benefits of an improved deferasirox formulation (film-coated tablet).*
4. ACE 536-04 (EudraCT 2012-002499-15, Acceleron Pharma); *A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β -Thalassemia;*
5. ACE 536-06 (EudraCT 2014-001281-94, Acceleron Pharma); *An Open-Label Extension Study to Evaluate the Long-Term Effects of ACE-536 in Patients with β -Thalassemia Previously Enrolled in Study A536-04;*
6. SPD602 (EudraCT 2011-005675-16, Shire Dev. LLC, USA); *A Phase 2, 24 Week, Randomized, Open Label, Multi-Center Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Two SSP-004184 (SPD602) Doses in the Treatment of Chronic Iron Overload Requiring Chelation Therapy;*
7. MIOT - Myocardial Iron Overload in Thalassaemia: T2* Multislice non invasive RM for cardiac iron overload assay, CNR, Pisa.
8. CICAL670AIT12 (EudraCT 2013-002747-28, Novartis) *Complications in Endocrine system in patients with transfusion dependent ThAlassemia: a multicenter, openlabel, single arm, interventional phase IV study, to evaluate the effect of deferasirox on endocrine*

CICL670AIT-14 – Novartis; *A retrospective data collection study to assess the long term renal safety of deferasirox in patients with transfusional hemosiderosis who were enrolled into the registration studies;*

THALAMOSS (Grant agreement for collaborative project 306201) *THALAssaemia MODular Stratification System for personalized therapy of beta-thalassemia.* THEME [HEALTH.2012.1.2-1] [Development of technologies with a view to patient group stratification for personalised medicine applications]

Coordinator of HUB & SPOKE Rare Anaemia Regional Sites Net.

Database administration: clinical report management and administration; local database structuring, designing and building and related procedures; documentation, evaluation and standard statistical analysis of data merging and derived datasets; database maintenance.

- *Dates (from – to)*
- *Name and address of employer*
- *Type of business or sector*
- *Occupation or position held*

14 Apr 2014 – ongoing

Consorzio Ferrara Ricerche – University of Ferrara - Via Savonarola, 9 – 44121 Ferrara (Italy)

Unit of Paediatric Haematology and Oncology - Department of Growth and Development-Azienda Ospedaliero-Universitaria S.Anna, Cona-Ferrara (Italy)

1-Data Manager AIEOP-LH (Italian Association of Paediatric Haematology and Oncology)

2-Standard Statistical Analysis

3-Occasional teaching assistance

Data Manager & Local Study Coordinator in accordance with study protocol requirements and in compliance with ICH – GCP guidelines.

Protocols:

- EuroNet PHL-LP1 - *International clinical trial on Hodgkin Lymphoma in children and adolescents* (EudraCT no. 2007004092-19, Martin Luther University of Halle/Wittenberg; Italian Coordinating Site: Ferrara).
- Inter-B-NHL Ritux 2010 - *Intergroup trial for children or adolescents with B-cell NHL or B-AL: evaluation of rituximab efficacy and safety in high risk patients* (EudraCT no. 2010-019224-31).

Clinical trials monitoring assuring adherence to GCP, company policies and local regulations, investigator integrity, and compliance with study procedures; supervising study conduct according to GCP requirements and all applicable laws.

Preparing database structures, designing and building related procedures documentation, evaluation and analysis of data merging and derived datasets; database maintenance.

Occasional teaching subjects: Biology and microenvironment of HL, AML, ALL.

- *Dates (from – to)*
- *Name and address of employer*
- *Type of business or sector*
- *Occupation or position held*

04 Feb 2008 – 30 Apr 2010

University of Verona – Department of Life Sciences and Reproduction- Unit of Paediatrics-Policlinico G.B. Rossi, P.le Scuro, 4 – 37134 Verona (Italy)

Missionary at Hopital Autonome de Ngozi, Ngozi – BP 6, Burundi

Responsible of Clinical Laboratory and Blood Bank Coordinator – Biometrician – Training of personnel

Clinical Laboratory. Theoretical and practical laboratory medicine training, GCP and lab TQM. Implementation and management of laboratory resources. Coordination of provincial hospitals and centralisation of specific lab analysis.

Local blood bank. Organisation and management.

Training: technicians, physicians, nurses, and auxiliary personnel.

Management and standardisation of clinical procedures, hygiene, special waste

- *Main activities and responsibilities*

management and disposal as per international WHO guidelines.
Standard statistical analysis: Epidemiology, haematology and most common parasitic and viral diseases.

- *Dates (from – to)*
- *Name and address of employer*
- *Type of business or sector*

15 Nov 2007 – 15 Apr 2010

University of Verona – Department of Life Sciences and Reproduction- Unit of Paediatrics-Policlinico G.B. Rossi, P.le Scuro, 4 – 37134 Verona (Italy)
Missionary at Université du Burundi – Institut Universitaire des Sciences de la Santé – BP 137, Ngozi
Teacher
Histology and Human Anatomy.
Responsible of examining board.

- *Occupation or position held*
- *Main activities and responsibilities*

- *Dates (from – to)*
- *Name and address of employer*

12 AUG 2005 – 11 JUL 2007

1-Emiliano De Marco Italian Association (ONLUS)
2-IBO Italia NGO, Via Montebello, 44121- Ferrara (Italy)
St. Orsola Catholic Hospital, Matiri Mission, Tharaka District, P.O. Box 41, 60200 Meru, Eastern Province – Kenya
Clinical Laboratory and Ministerial Consultant
1-Responsible of Clinical Laboratory Service (ONLUS Emiliano De Marco)
2-Ministerial Consultant for Foreign Ministry, Project: *Prevention of spreading and surveillance of HIV/AIDS mother-to-child transmission in Tharaka District* - Reg. code 7676/IBO/KEN

- *Type of business or sector*
- *Occupation or position held*

- *Main activities and responsibilities*

Clinical Laboratory:

Setting up and conduction; technologists, technicians, laboratory officers and assistants staffing; competences, duties and responsibilities; upgrading and career development. Introduction and application of GCP in district health care. Coordination of regional hospital departments identifying needs and providing services.

TQM: Standard operating procedures (SOPs) in pre-analytical, analytical and post-analytical lab phases, equipment/instrument management and maintenance service. Relevance, interpretation and clinical information impact of analytical results and reporting and recording standardization.

Training: General laboratory conduction; diagnostic tests ability to indicate presence/absence of disease; significance of reference ranges in clinical practice, local reference ranges assessment (SI base/derived units as per WHO recommendations); basic epidemiology on public clinical health. *Mobile laboratory:* regulations and practice; specimen collection procedures and operator/patient protective measures; requirements of specimen referral system. *Logistics:* Expenses estimation; management of storage and inventory register; selection of essay and resolution of fault in finance management. *Health and safety programme:* Risk assessment with identification of risk group micro-organisms; safety measures application against acquired infections; use and maintenance of biological safety cabinets. Transporting specimen regulations (Safety in health-care laboratories – WHO). *Hazards:* Classification, storage, use of flammable, oxidizing, toxic, harmful, irritating, corrosive, explosive chemicals and preventing accidents programme. Decontamination and recycling and disposal of special waste. Fire fighting equipment and guidelines to reduce fire risk. *Software basic:* Microsoft Office (Excel, Access, Word and Power Point).

Blood transfusion service

In collaboration with the Regional Transfusion Centre, Embu, Kenya. Application of international guidelines/SOPs in tropical countries; QA and management responsibility; blood donations in critical situations; screening of regional donors; transfusion reaction investigation; statistical management and reports for the Regional Centre.

Medical Seminars conduction

Medical topics addressed to specific sector personnel.

- *Dates (from – to)*
- *Name and address of employer*
- *Type of business or sector*
- *Occupation or position held*
- *Main activities and responsibilities*

01 SEP 1997 – 31 JAN 2005

Consorzio Ferrara Ricerche – University of Ferrara - Via Savonarola, 9 – 44121 Ferrara (Italy)

Day Hospital Thalassaemia, Department of Paediatrics and Endocrinology
Blood Bank

1-Data manager

2-Clinical researcher (observational and interventional trials - phases II-III-IV)

Data managing and creation of local databases and clinical data management.

Standard Statistical Analysis: *Survival analysis and causes of death* in thalassaemia patients since 1956.

Auxo-endocrinological studies in collaboration with Giambone Thalassaemia Association, Cagliari (Italy) and Institut für Sozial und Präventivmedizin der Universität, Zürich, Switzerland.

Observational studies and laboratory: Endocrinopathies and cardiac disorders; ACTH tests and biometrical evaluation of bone age (TW₂₀) in paediatric patients; statistical evaluation of LIC by SQUID vs. iron compound by liver biopsy; effect of Interferon-Ribavirin therapy in patients affected by HCV; DNA spermatid cells damage, in collaboration with Departments of Obstetrics and Gynaecology and Haematology, UCL London - MCR Reproductive Biology Unit, Edinburgh, UK.

Comparative study: Chelating therapy with desferrioxamine and deferiprone on bone metabolism in thalassaemia major (Chiesi S.p.A.; Rizzoli Orthopedic Institut –IOR-, Bologna, Italy).

Evaluation study: Liver iron compound (LIC) by SQUID in collaboration with Abt. Medizinische, Biochemie, Universitätskrankenhaus Eppendorf, Hamburg, Germany and Microcitemia Centre, Turin, Italy.

Clinical Trials:

“Safety and efficacy of red blood cells stored in 0.5 CPD/ Erythro-sol versus in CPD/SAG-M in transfusion-dependent thalassaemia patients” (Fenwal R&D Group, Baxter Europe, Belgium) - S. Anna Hospital and Department of Biomedical Studies, University of Ferrara, Italy

“Checking of performance and safety of equipments and blood/plasma filtration systems” and “Bibliographic investigation and scientific reports priming pertaining to the above-mentioned activity” (Biofil S.r.L., Italy) – Blood Bank, St. Anna Hospital, Ferrara, Italy.

Pharmacokinetic and pharmacodynamic of oral chelating agent Deferiprone (Phase II-III, Apotex S.p.A., Canada)

Oral chelating treatment with ICL670 (Feriprox) in thalassaemia patients (Novartis S.p.A.)

Biometrical evaluation of Feriprox vs. Deferiprone and Desferal chelating agents (Phase IV, Novartis, S.p.A.).

- *Dates (from – to)*
- *Name and address of employer*
- *Type of business or sector*
- *Occupation or position held*
- *Main activities and responsibilities*

March 1991-April 1994

Azienda Ospedaliero-Universitaria S. Anna, Corso Giovecca, 203 – 44100 Ferrara (Italy)

Department of Nuclear Medicine (RIA Laboratory)

Analyst

Radio-Immune assays: thyroid, pituitary, steroid and ovarian hormones,

pregnancy tests. Preliminary study: *Circadian Cycles - Hormones evaluation in health population.*

EDUCATION AND TRAINING

- *Dates (from – to)*
- *Name and type of organisation providing education and training*

February 1989-February 1990

Azienda Ospedaliero-Universitaria S. Anna, Corso Giovecca, 203 – 44121 Ferrara (Italy)

- *Principal subjects/occupational skills covered*
- *Title of qualification awarded*

- *Date*
- *Name and type of organisation providing education and training*
- *Principal subjects/occupational skills covered*
- *Title of qualification awarded*

- *Dates (from – to)*
- *Name and type of organisation providing education and training*
- *Title of qualification awarded*

MOTHER TONGUE

OTHER LANGUAGES

- *Reading skills*
- *Writing skills*
- *Verbal skills*

- *Reading skills*
- *Writing skills*
- *Verbal skills*

TECHNICAL SKILLS
AND COMPETENCES
With computers, specific kinds of equipment, machinery, etc.

DRIVING LICENCE(S)

PROFESSIONAL TRAINING
Stages

Clinical Laboratory. Post-graduate training: electrophoresis, haematology, clinical chemistry, microbiology, serology, flow cytometry.

Professional Biologist Doctor with National Board registration no. 034327

15 Dec 1988

University of Ferrara, Italy

Biological Sciences

Bachelor of Science degree in Biology

27 Jul 1979

Science High school A. Roiti, Ferrara, Italy

Baccalauréat in Scientific studies

ITALIAN

ENGLISH

PROFICIENT USER

PROFICIENT USER

PROFICIENT USER

FRENCH

PROFICIENT USER

PROFICIENT USER

PROFICIENT USER

Past: 1985-1988 IBM-XT computer in connection with CDC CYBER 180/860 A (disabled at the present) - C.I.N.E.C.A. (Inter-University Electronic Centre, North-eastern Italy) Casalecchio di Reno-Bologna using N.O.S. (Network Operating System) and SPSS-X (Statistical Package for Social Sciences for biometrical evaluations). DBF-III.

Present:

Microsoft Office (Access, Excel, Power Point, Word)

Statistical Softwares: Statgraphics (Manugistics), MedCalc, PSP.2K (Personal Statistic Package, Servizio Fisica Sanitaria-S.Anna Hospital, Ferrara, Italy)

Clinical laboratory instruments: Haematology coulter, clinical chemistry and coagulation analysers, flow cytometer, PCR.

B

“Generalità ed applicazioni cliniche dei marcatori tumorali” (General principles and clinical applications of tumour markers). September 21, 1990 - Ares-Serono Diagnostici, Aula Magna University of Modena, Italy.

Monitoraggio specifico della Ciclosporina con il metodo in fluorescenza polarizzata (FPIA): valutazioni e prospettive” (Specific monitoring of Cyclosporin with polarized fluorescence (FPIA): evaluations and expectations). October 17, 1990 - Abbott S.p.A. Divisione Diagnostici, Palazzo dei Congressi, Bologna, Italy.

“Markers del metabolismo osseo” (Bone metabolism markers). October 24, 1990 - Medical System S.p.A., Nuovi Istituti Biologici, University of Ferrara, Italy.

“Applicazione clinica degli anticorpi monoclonali” (Clinical application of monoclonal antibodies). February 2, 1991 – Nuovi Istituti Biologici, University of Ferrara, Italy.

“Osteoporosi. Aspetti diagnostico-terapeutici” (Osteoporosis. Diagnostic and therapeutic aspects). May 30-31, 1991 - Nuovi Istituti Biologici, University of Ferrara, Italy.

“Evaluation of CA 549 in malignant neoplasms of the human breast”. October 13-17, 1991 – Poster; XIX meeting - Scuola di Medicina dell’Istituto di Ostetricia e Ginecologia, and the International Society of Oncodevelopmental Biology and Medicine (I.S.O.B.M.), Siena, Italy.

“Eziopatogenesi delle epatiti virali da HBV, HCV e nuovi virus epatotropi. Interazioni diagnostiche e terapeutiche” (Etiopathogenesis of HBV and HCV viral hepatitis). September 24-26, 1997 – Meeting Centre of Grand Hotel Baglioni, Parma, Italy - Monotematica AISF 1977

“Il comportamento alimentare” (Nutrition behaviour). October 23, 1997 – Centro Congressi of Ferrara: Divisione Pediatrica – Prima Divisione Medica - Servizio Dietetico - Clinica Pediatrica - Clinica Psichiatrica, Azienda Ospedaliera-Universitaria, Ferrara, Italy.

“Trattamento dell’epatopatia cronica nel paziente talassemico” (Treatment of chronic epatopathy in thalassaemia patient). November 27, 1997 - Roma, Italy.

“2nd International Workshop on Growth and Endocrine Complications & Reproduction in Thalassaemia” - April 2-4, 1998 - Fondation Ares-Serono, Centro Congressi, Ferrara, Italy.

“Epatopatia nella Talassemia (Epatopathy in Thalassaemia)”. A.C.S.A. meeting, S.I.E.D.P. group, p.58-67, Catanzaro, May 8-9, 1998.

“Adolescenza: verso un approccio multidisciplinare” (Adolescence: towards a multi-disciplinar approach) May 8-9, 1998 - Associazione Catanzarese per gli Studi Auxologici (A.C.S.A.) – Endocrine Complications in Chronic Diseases Group (S.I.E.D.P.) - Hotel Guglielmo, Catanzaro, Italy. Presentation: “Epatopatia nella Talassemia”

“Corso di aggiornamento della Società Italiana di Adolescentologia” (Refresher course of Italian Society of Adolescence) June 2-3, 2000 – Società Italiana di Medicina dell’Adolescenza (S.I.M.A.) – Ferrara, Italy

“Novità in tema di Emoglobinopatie” (Haemoglobinopathies update). Novembre 16, 2002, Nuove Cliniche, Azienda Ospedaliera-Universitaria Arcispedale S. Anna, Ferrara, Italy

“Corso di aggiornamento relativo al software S.I.T” (Sistema Informatico Talassemia) per la gestione della cartella clinica computerizzata” (Refresher course on S.I.T. to manage the clinical report in Thalassaemia Centre). Dicembre 4, 2002 - EMATIC S.r.l., Isola delle Femmine, Palermo, Italy

“Investigators’ Meeting CICAL670A0107”. January 13-15, 2003 – NOVARTIS, Hotel Montparnasse, Parigi, France

“Investigators’ Meeting Protocol CICAL670A0107”. Mars 10-11, 2003 – NOVARTIS, Hotel Mediterraneo, Cagliari, Italy

“EDC Workshop and ICH-GCP training”. April 11, 2003 – NOVARTIS, Novartis Italia, Origgio (MI), Italy

“Investigators Meeting Studio CICAL670A0112”. October 29-30, 2003 – NOVARTIS, Excelsior Hotel, Milano, Italy

“Riunione Ricercatori Italiani coinvolti negli studi ICL670” (Italian Researchers meeting on ICL670 study). May 12, 2004 Roma, Italy

“Metabolismo osseo e terapia chelante” (Bone metabolism and chelation therapy). Ottobre 15, 2004 III Congresso Nazionale SO.S.T.E., Oct 14-16, 2004 Cassana (FE), Italy

“Le complicanze renali in talassemia” (Renal failures in thalassaemia). Ottobre 16, 2004 III Congresso Nazionale SO.S.T.E., Oct 14-16, 2004 Cassana (FE), Italy

“III International Meeting – DREAM – Un sogno per l’Africa: bambini senza AIDS” (A dream for Africa: children without AIDS). May 27, 2005 Rome, Italy

“Training on African patient. Focus on the laboratory aspects”. August 1-10, 2005 – Arusha – Tanzania

“In Africa. Esperienze pediatriche Italiane” (Meeting: *Italian paediatric experiences in Africa*). September 10-11, 2010 –Palazzo Costabili, Ferrara, Italy. Presentation: “Il Laboratorio Africano Essenziale” (The African essential clinical laboratory. Personal experience).

“Gruppo di Lavoro “Linfoma di Hodgkin” (Hodgkin’s Lymphoma Workshop). September 30, 2011 – AIEOP (Paediatric Oncology/Haematology Italian Association) Clinic of Paediatrics – S. Anna Hospital, Ferrara (Italy)

“EuroNet-PHL group meeting”, February 10-11, 2012 Dublin, Ireland

“Il futuro delle Emoglobinopatie” (*The future of the haemoglobinopathies*)– VII National Conference, S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopathies), 27-29 September, 2012 – Brindisi (Mesagne), Italy

“ThalaMoss. From basic research to novel applications on the road of personalized treatment of thalassaemia” 1st Thalamoss Scientific Meeting, Ferrara, January 14, 2013 – Department of Life Sciences and biotechnology, Univeristy of Ferrara, Italy

“Giornata Mondiale delle Malattie Rare- Formazione, Informazione ed Ascolto in Emilia-Romagna – IV Edition” (*World rare diseases day – Training, Updating, and Listening in Emilia Romagna*) - Regione Emilia-Romagna – Bologna – March 2, 2013

“Exjade. Ridefinire la Ferrochelazione” (*Exjade. Re-defining the iron chelation treatment*) – Milan, 22-23 March, 2013

Hub&Spoke Net Meeting – Regione Emilia-Romagna – Bologna, April 16, 2013

Hub&Spoke Net Meeting – Regione Emilia-Romagna – Bologna, April 22, 2013

“Chiltern ICH-GCP Training slides version 1_Final_07-Sept-2012”
Clinical Trial ACE 536-04

“Opis ICH-GCP and Project specific eCRF Training 17-Jan-2013” – Protocol 2012-101 – Antiviral therapy associated with Deferasirox in thalassaemia patients.

“GCP training through attendance at investigators meetings and/or participation in clinical trials 24-May-2013” – Protocol Inter-B-NHL Ritux 2010 Intergroup trial for Children or adolescents with B-Cell NHL or B-AL: evaluation of Rituximab efficacy and safety in high risk patients

“Rave EDC Essentials for Clinical Research Coordinators” Certified Professional - Clinical Research Coordinator ID# MDSO3224880 - Medidata University, 11-Sep-2013

“13th International Conference on Thalassaemia & Hemoglobinopathies”
Thalassaemia International Federation World Congress – Abu Dhabi, United Arab Emirates, 20-23 October, 2013

“Ricerca e Innovazione nella cura della Talassemia” (*Research and Innovation improving the clinical care of Thalassaemia*), 15 March, 2013 – Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy)

“Talassemia Major e Osteoporosi” (Thalassaemia Major and Osteoporosis) - 11 June, 2013 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy)

Seminar: **“Talassemia major e osteoporosi”** (Thalassaemia Major and Osteoporosis) -9 September, 2013 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy)

“Epatopatia cronica HCV nel paziente talassemico” (*Chronic HCV hepatopathy in thalassaemia patient*) – 12 October, 2013, Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy)

“Riattivazione della sintesi di HbF dopo trapianto di midollo. Trapianto di midollo nella drepanocitosi e nella talassemia” (Reactivation of HbF synthesis after bone marrow transplantation. Hematopoietic stem cell transplantation in thalassaemia and sickle cell anemia)- 14 Jan 2014 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy)

A536-04 ERT SITEpro Training – Acceleron Pharma, Inc. 07-Apr-2014

“I livelli di concentrazione del ferro epatico. Metodi a confronto” - (Liver Iron Compound. Comparison among methods available for assessment of liver iron levels) – Seminar, 11 April, 2014 - Azienda Ospedaliero-Universitaria S. Anna, Cona-Ferrara (Italy)

“Clinical Complication in Sickle Cell Disease and β -Thalassaemia & Thalamoss GA Meeting”, Nicosia, Cyprus 25-27 June 2014

“Second International Inter-Group Study for Classical Hodgkin’s Lymphoma in Children and Adolescents” – Ferrara, 22-23-Sep-2014

“La Citometria a Flusso: Principi ed Applicazioni Cliniche” (Flow cytometry: principles and applications). Arcispedale S. Anna di Ferrara, Vol. XL, n°1, Jan-Mar, 1990.

“Evaluation of CA 549 in malignant neoplasms of the human breast”. Poster, XIX meeting of International Society of Oncodevelopmental Biology and Medicine (I.S.O.B.M.), Siena, Oct 13-17, 1991.

“Modification of serum ferritin levels after Deferiprone administration to patients affected by β -Thalassaemia Major”. Poster. 8th International Conference Oral Chelation in the Treatment of Thalassaemia and Other Diseases, Sept 19-21, 1997, Corfù.

“Growth, endocrine complications and reproduction in Thalassaemia Major”. Abstract (pag. 96) - 1st International workshop on thalassaemia – New Delhi, Oct 30- Nov 5, 1998

“Fertility in males with thalassaemia”. Abstract#1503 – 7th International conference on thalassaemia and haemoglobinopathies. Bangkok-Thailand, May 31- June 4, 1999.

“ β -Thalassaemia”. Collaboration in Book: **“Problemi Ambulatoriali di Medicina dell’Adolescenza”**, Pacini editor, p.254-258.

“Epidemiology and chelation therapy effects on glucose homeostasis in thalassaemic patients”. Gamberini MR, Fortini M, Gilli G, Testa MR, De Sanctis V. J Pediatr Endocrinol Metab. 1998;11 Suppl 3:867-9.

“Clinica della β -Talassemia Major” (Clinical aspects of β -Talassemia Major). Title: **“Clinica e Terapia della Talassemia”**, collana **“Le emoglobinopatie oggi: dalla terapia alla prevenzione”** A. Maggio, Società Editrice Europea, Firenze, 2000.

“Effetto della filtrazione sulle popolazioni eritrocitarie di differente età” (Effect of filtration on erythrocytes of different age). Abstract – Haematology Meeting, Rimini 2000.

“Factors influencing final/near-final height in 12 boys with central precocious puberty treated with Gonadotrophin-releasing hormone agonists”. Rizzo V., De Sanctis V., Corrias A., Fortini M., Galluzzi F., Bertelloni S., Pozzan G., Cisternino M., Pasquino A.M., Italian Study Group of Physiopathology of Puberty Journal of Paediatric Endocrinology & Metabolism, 13, 781-786 (2000)

“Latex allergy in multitransfused thalassaemia patients”. Blood, Journal of the American Society of Haematology, 96, 23b, abstract# 3755 (November, 2000)

“Meccanica ventricolare sinistra in giovani adulti con talassemia major in terapia trasfusionale cronica. Valutazione echo-doppler e correlazione con dati ematologici” (Left ventricular mechanism in young thalassaemia major adult under chronic transfusion treatment. Echo-Doppler evaluation and correlation with haematological data). Abstract - XXX Cardiology National Congress (ANMCO) – Firenze, May 30 – Jun 2, 1999

“Left ventricular mechanics in young adults with transfusion-dependent β -Thalassaemia Major”. Abstract - Società Latina di Cardiologia Pediatrica, VIII International Meeting, Roma May 23-26, 1999

“Left Ventricular Remodeling, Systolic Function, and Diastolic Function in Young Adults with β -Thalassemia Intermedia. A Doppler Echocardiography Study”. Vaccari M, Crepaz R, Fortini M, Gamberini MR, Scarcia S, Pitscheider W, Bosi G. Chest. 2002 Feb;121(2):506-12.

“Left ventricular remodelling, and systolic and diastolic function in young adults with β -thalassaemia major: a Doppler echocardiographic assessment and correlation with haematological data”. Bosi G, Crepaz R, Gamberini MR, Fortini M, Scarcia S, Bonsante E, Pitscheider W, Vaccari M. Heart. 2003 Jul;89(7):762-6.

“Alterazioni della colonna vertebrale nei pazienti talassemici in trattamento chelante” Abstract-(Spine defects in thalassaemia patients under chelation therapy). V Paediatric Neuroradiology National Congress – Firenze May 11-13, 2000

“Compliance alla terapia ferrochelante con Deferroxamina” (Compliance to the iron chelation therapy with Desferroxamine). Book. Translation from English version, intended for care providers. Editor: Thalassaemia International Federation (TIF), Jul, 2000

“Healing of leg ulcers with hydroxyurea in patients with thalassaemia intermedia”. Abstract - 11th International Conference on Oral Chelation in the treatment of thalassaemia and other diseases – Mar 22-25, 2001 – Catania - SO.S.T.E. Notiziario, vol.2, n°1, p.119 – Apr., 2001

“Healing of Leg Ulcers with Hydroxyurea in Thalassaemia Intermedia Patients with Associated Endocrine Complications”. Gamberini MR, Fortini M, De Sanctis V. Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:319-22.

“HCV and HGV infection, iron overload and liver disease in multitransfused patients with thalassaemia and persistently normal or abnormal transaminase levels”. Abstract - 11th International Conference on Oral Chelation in the treatment of thalassaemia and other diseases – Mar 22-25, 2001 – Catania - SO.S.T.E. Notiziario, vol.2, n°1, p.118 – Apr., 2001

“Growth and Chelation”. Publication - 11th International Conference on Oral Chelation in the treatment of thalassaemia and other diseases – Mar 22-25, 2001 – Catania - SO.S.T.E. Notiziario, vol.2, n°1, p.41 – Apr., 2001

“Effects of chelation therapy on bone metabolism in β -thalassaemia”. Poster – VI Congresso Nazionale IORS (Italian Orthopaedic Research Society) – Istituti Ortopedici Rizzoli, Bologna, Italy. Apr. 22-23, 2004-10-17

“Diabetes Mellitus and Impaired Glucose Tolerance in Thalassaemia Major: Incidence, Prevalence, Risk Factor and Survival in Patients Followed at Ferrara Centre”. Gamberini MR, Fortini M, De Sanctis V, Gilli G, Testa MR. Ped Endocr Rev. 2004 Dec;2 Suppl 2:285-91.

“HCV and HGV infection, iron overload and liver disease in multitransfused patients with thalassaemia and persistently normal or abnormal transaminase levels”. Gamberini MR, Francesconi R, Fortini M, Cavazzini L, Lari F, Scapoli C, Ballardini G, De Sanctis V, Bianchi FB. Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:259-66.

“Paraplegia due to Spinal Cord Compression by Extramedullary Erythropoietic Tissue in a Thalassaemia Intermedia Patient with Gynecomastia Secondary to Cirrhosis: Successful Treatment with Hydroxyurea”. Gamberini MR, Fortini M, De Sanctis V. Pediatr Endocrinol Rev. 2004 Dec;2 Suppl 2:316-8.

“Impact of Iron-Chelation therapy on Growth and Endocrine Functions in Thalassaemia”. Roos M Gasser T Fortini M Raiola G Galati MC De Sanctis V. J Pediatr Endocrinol Metab. 2006 Apr;19(4):471-80

“Chelation therapy and bone metabolism markers in thalassemia major”. Pratelli L, Verri E, Fortini M, Marconi S, Zolezzi C, Fornasari PM, Gamberini MR, De Sanctis V. *J Pediatr Endocrinol Metab.* 2006 Nov;19(11):1335-42.

“Spermatozoal DNA damage in patients with β thalassaemia syndromes”. Perera D, Katz M, Fortini M, Gamberini MR, De Sanctis V. *Pediatr Endocrinol Rev* (2008) Volume: 6 Suppl 1, Pages: 185-9

“Hystology”. Lecture notes on: « *Les tissus en général ; Les tissus épithélieux de revêtement et glandulaires ; Les tissus conjonctifs ; le tissu vasculaire ; le tissu nerveux* ». 20-28 November, 2007/June 2008. Institut Universitaire des Sciences de la Santé – Université de Ngozi – B.P. 137 Ngozi, Burundi.

“Anatomy”. Lecture notes on : “*Osteology ; Arthrology; Myology*”. November, 2007 – April, 2010. Institut Universitaire des Sciences de la Santé – Université de Ngozi – B.P. 137 Ngozi, Burundi.

“Thyroid nodules and thyroid cancer in transfusion-dependent β -thalassaemia patients” – Poster. XII Conference on Thalassaemia – Thalassaemia International Federation (TIF). Antalya (Turkey) May, 2011

“Seasonal pattern in the occurrence of Hodgkin Lymphoma registered in the AIEOP MH’96 and LH2004 studies”. R.Burnelli^{1*}, E. Fabbri¹, G.Guerrini¹, P. Gallo¹, S.Rinieri¹, M.Fortini¹, and R.Rondelli² on Behalf of the Italian Association of Pediatric Hematology and Oncology (AIEOP). (¹Pediatric Department, Ferrara University, Italy; ²Hematology and Oncology Unit-Bologna University, Italy). 1st international symposium on childhood, adolescent, and young adult Hodgkin Lymphoma - Arlington, Va, (USA) - May 12–14, 2011 I-ISCA AHL abstracts-poster

“Microenvironment Biology of Hodgkin’s Lymphoma, Acute Lymphoblastic Leukaemia and Acute Myeloid Leukaemia” – 9th of June, 2011, Lesson – V year specialisation in Paediatrics - Paediatric Section, S.Anna Hospital, Ferrara

“Il laboratorio Africano Essenziale”. Publication. *Medico e Bambino* (Italian professional review for paediatricians and physicians). Vol 30, number 7; pg.439-440. September 30, 2011

“Correzione della carenza di Vitamina D con Colecalciferolo in 23 pazienti politrasfusi affetti da β -talassemia” (*Deficit of Vitamin C treated with Cholecalciferol in 23 multitransfused β -thalassaemia patients*) – Poster - VII National Conference, S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopathies), 27-29 September, 2012 – Brindisi (Mesagne), Italy

“Livelli di 25(OH)vitD ed epatopatia cronica HCV correlata, sovraccarico marziale, complicanze cardiache ed endocrine nei pazienti con Talassemia Major” (*25(oh)vitD levels and chronic hepatitis C, iron overload, cardiac and endocrine complications in β -thalassaemia major patients*) - Poster - VII National Conference, S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopathies), 27-29 September, 2012 – Brindisi (Mesagne), Italy

“Eventi avversi in corso di terapia con PEG-INF+RIBA per epatite cronica HCV in pazienti politrasfusi con β -talassemia” (*Adverse events in the course of peg-INF+RBV antiviral treatment in multitransfused β -thalassaemia patients with chronic hepatitis C*) - Poster - VII National Conference, S.I.T.E. (Italian Society of Thalassaemia and Haemoglobinopathies), 27-29 September, 2012 – Brindisi (Mesagne), Italy

“Insufficiency fractures and asymptomatic vertebral fractures in adult patients with Beta-Thalassaemia Major” – 13th International Conference on Thalassaemia & Hemoglobinopathies –Poster – 20-23 Oct 2013 – Abu Dhabi (UAE)

“Adverse effects during PEG-INF+RBV treatment of chronic hepatitis C in multitransfused β -thalassaemia patients” – Poster - 13th International Conference on Thalassaemia & Hemoglobinopathies –Poster – 20-23 Oct 2013 – Abu Dhabi (UAE)

“25(OH)vitD levels and HCV infection, iron overload, cardiac and endocrine complications in patients with Thalassaemia Major” – Poster - 13th International Conference on Thalassaemia & Hemoglobinopathies –Poster – 20-23 Oct 2013 – Abu Dhabi (UAE)

“Clinical complications in Sickle Cell Disease and β -Thalassaemia” – International Conference – 25-27 June 2014 – Nicosia, Cyprus

“Terapia combinata deferasirox+desferioxamina in un caso di grave siderosi cardiaca ed epatica con disfunzione cardiaca: normalizzazione dei depositi e della funzione cardiaca” (Combined chelation therapy with deferasirox and deferoxamine. A severe cardiac and hepatic siderosis in cardiac left ventricular dysfunction case: normalisation of cardiac iron overload and cardiac function) – Poster, VIII National Congress S.I.T.E., 9-11 Oct 2014, Genova (Italy)

“Scompenso cardiaco da grave siderosi: completo ripristino della funzionalità d’organo in terapia con deferasirox” (Heart failure in severe siderosis case: a complete cardiac function reactivation in the course of deferasirox treatment) – Poster, VIII National Congress S.I.T.E., 9-11 Oct 2014, Genova (Italy)

“Susceptibilità all’infezione da Parvovirus B19 in pazienti politrasfusi con talassemia” (Politransfused thalassaemia patient susceptible to Parvovirus-B19 infection) – Poster, VIII National Congress S.I.T.E.- 9-11 Oct 2014, Genova (Italy)

“Siderosi cardiaca ed epatica nei pazienti talassemici trasfusione-dipendenti e non: stato attuale presso il centro di Ferrara” (Cardiac and hepatic siderosis in transfusion and non transfusion-dependent thalassaemia patients: the current status at Ferrara Centre) - Poster, VIII National Congress S.I.T.E.- 9-11 Oct 2014, Genova (Italy)

“Neoplasie maligne e benigne diagnosticate nella popolazione talassemica del centro di Ferrara” (Malignant and benign tumours diagnosed among the thalassaemia patients at Ferrara Centre) – Poster, VIII National Congress S.I.T.E.- 9-11 Oct 2014, Genova (Italy)

National Board Registration no. 034327

Ferrara,
08 October, 2014

Monica Fortini

